Mike Hollan

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.

Yerem Yeghiazarians, MD, explains how understanding how various cells react differently to stress impacts how damaged cells may potentially be treated.

Drug pricing restrictions are likely to impact drug launches, especially for medications expected to be sought after by Medicare patients.

As opposed to starting with a target disease, Yerem Yeghiazarians, MD discusses how Soley instead focused on developing a method of identifying broad compounds.

While they may be linked, the administration’s DTC drug coupon site is not necessarily the entirety of its MFN efforts.

Yerem Yeghiazarians, MD, discusses the importance of understanding why certain cells (like cancer cells) can survive in situations that would kill other healthy cells.

For pharma products, ensuring proper delivery requires the majority of work to occur before the product hits the road.

eHealth’s vice president of consumer enablement discusses pricing and cost issues with GLP-1s.

While the space has traditionally been dominated by smaller biotechs, that may be changing.

Inclusive Capital Partners sold a stake worth about 0.9 % of the company.

Making changes in the pharma industry in operations is a slightly more expensive process because of larger compliances and regulatory pieces involved.

FDA has provided opportunities for R&D in rare disease, although recent developments have caused significant setbacks to occur.

Pharma products face unique issues related to chain-of-custody and cold chain.

In the final part of his conversation with Pharmaceutical Executive, Aravo CCO Dave Rusher discusses the various regulatory updates around the world in the pharma and AI space.

Limited patient populations require sponsors to adapt their practices when working in the rare disease space.

While digital clinical trials provide more opportunity, they also present unique challenges that can significantly impact the trial results.

The ruling places a hold on any decisions made by the council, although the government does plan to appeal the ruling.

Dave Rusher, CCO at Aravo, explains the relationship between large, publicly available LLMs and how private LLMs might benefit the pharma industry.

Jiang Li, CEO of Vivalink, continues his conversation with Pharmaceutical Executive, this time discussing the impact of continuous monitoring on patient adherence.

RDEP is a sign that regulators acknowledge that rare disease is a unique space that requires special attention.

Vivalink’s CEO Jiang Li, PhD, discusses the importance of including as much information with clinical data as possible.

Aravo CCO Dave Rusher discusses the risk of third-party AI usage at pharma companies.

Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.

Ron Wyden led 7 Democrats demanding details from Pfizer, AstraZeneca, Novo Nordisk, and Eli Lilly.

The deal comes after Novo took legal action against Hims to prevent the company from offering compounded GLP-1 medications.

The vaccine chief briefly left the role last summer before almost immediately returning to it.

Pharma companies choosing between Salesforce and Veeva’s CRM has larger implications than many expect.

The drug is part of the Commissioner’s National Priority Review Voucher program.

In the second part of his conversation with Pharmaceutical Executive, Ajna Biosciences CEO Joel Stanley explains the complexities of getting a botanical drug approved.

Alice Valder Curran discusses how the industry continues to strategize around this complicated order.